Exenatide treatment in 3xTg-AD mice with streptozotocin (STZ)-induced diabetes not only improved glucose metabolism by elevating plasma insulin and reducing plasma glucose and HbA1c levels but also reduced brain Aβ levels, highlighting its potential benefit in managing AD associated with T2D [91]. Here, INS is linked to type 2 diabetes mellitus.